The two cohorts are comparable, with the primary differences between the cohorts being that the PATH for PWS cohort was slightly older, and, consequently, had somewhat lower rates of growth hormone treatment, and incrementally lower baseline HQ-CT scores. Here, GH1 is linked to Prader-Willi syndrome.